Compugen (NASDAQ:CGEN) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Tuesday.
According to Zacks, “Compugen Ltd. is a pioneer in the fields of computational genomics and proteomics. The company combines the disciplines of mathematics and computer science with molecular biology to improve the understanding of genomics and proteomics, the study of genes and proteins. Compugen’s expertise in these areas is used to develop core technologies and platforms that are the basis for its products and services. These products and services are designed to enable life scientists to significantly enhance their research efforts in drug discovery. “
Separately, ValuEngine downgraded Compugen from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st.
An institutional investor recently raised its position in Compugen stock. Ark Investment Management LLC boosted its position in Compugen Ltd. (NASDAQ:CGEN) by 104.1% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 560,103 shares of the biotechnology company’s stock after purchasing an additional 285,653 shares during the period. Ark Investment Management LLC owned approximately 1.10% of Compugen worth $2,128,000 as of its most recent SEC filing. 17.43% of the stock is owned by institutional investors.
Compugen Company Profile
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.